Most Popular
-
1
Tensions heighten ahead of first president-opposition chief meeting
-
2
Seoul to provide housing subsidy to married couples with newborns
-
3
[KH Explains] No more 'Michael' at Kakao Games
![[KH Explains] No more 'Michael' at Kakao Games](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/28/20240428050183_0.jpg&u=20240428180321)
-
4
Rapper jailed after public street fight with another rapper
-
5
Woman gets suspended term for injuring boyfriend with knife
![[KH Explains] No more 'Michael' at Kakao Games](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/28/20240428050183_0.jpg&u=20240428180321)
-
6
Samsung chief bolsters ties with Germany’s Zeiss
-
7
NewJeans pops out ‘Bubble Gum’ video amid troubles at agency
-
8
Med schools expect 1,500+ new admission slots next year
-
9
Nominee for chief of anti-corruption body pledges 'independence, effectiveness'
-
10
[Grace Kao] Hybe vs. Ador: Inspiration, imitation and plagiarism
![[Grace Kao] Hybe vs. Ador: Inspiration, imitation and plagiarism](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/28/20240428050220_0.jpg&u=)
![[Grace Kao] Hybe vs. Ador: Inspiration, imitation and plagiarism](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/04/28/20240428050220_0.jpg&u=)
Celltrion applies for clinical trials for Remsima SC
By Korea HeraldPublished : June 16, 2016 - 16:46
[THE INVESTOR] Celltrion Inc. announced on June 16 that it has applied for a permit to carry out human clinical tests for Remsima SC.
Celltrion is an Incheon-based biotechnology firm headed by Seo Jung-jin.
Remsima SC is a new line of the autoimmune disease treatment Remsima. Unlike Remsima that requires intravenous injection, Remsima SC can be administered by the patient through subcutaneous injection, the company said. Remsima is a biosimilar based on Remicade developed by Jansen Global Services.
The clinical trials will be conducted on patients suffering from Crohn’s Disease, rheumatoid arthritis and ulcerative colitis.
Celltrion said that applications for clinical trials will also be filed in overseas markets including those in Europe and South America.
The company hopes to receive approval both here and abroad to roll out the product in 2018.
By Choi He-suk (cheesuk@heraldcorp.com)
Celltrion is an Incheon-based biotechnology firm headed by Seo Jung-jin.
Remsima SC is a new line of the autoimmune disease treatment Remsima. Unlike Remsima that requires intravenous injection, Remsima SC can be administered by the patient through subcutaneous injection, the company said. Remsima is a biosimilar based on Remicade developed by Jansen Global Services.
The clinical trials will be conducted on patients suffering from Crohn’s Disease, rheumatoid arthritis and ulcerative colitis.
Celltrion said that applications for clinical trials will also be filed in overseas markets including those in Europe and South America.
The company hopes to receive approval both here and abroad to roll out the product in 2018.
By Choi He-suk (cheesuk@heraldcorp.com)
-
Articles by Korea Herald
